Sandoz reports on October 27: Sandoz stock trades 1.66 percent higher

Published on 10/13/2026 at 13:44 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

First-half 2026 sales rose 5.00 percent at constant currency. Sandoz stock costs EUR 77.35 on October 13, 2026, up 1.66 percent on SIX.

Sandoz's next sales and revenue release is scheduled for October 27, 2026.
First-half 2026 sales rose 5.00 percent at constant currency.
Sandoz stock was EUR 77.35 at Lang & Schwarz on October 13, 2026 at 3:38 p.m. CEST, up 1.66 percent on SIX.
Morgan Stanley raised its target from CHF 55.00 to CHF 60.00 while keeping Underweight on October 6, 2026.

Sandoz, CH1243598427, Illustration mit AI erstellt.

Sandoz's next sales and revenue release is scheduled for October 27, 2026, while Sandoz stock was trading at EUR 77.35 at Lang & Schwarz on October 13, 2026 at 3:38 p.m. CEST. MarketScreener lists the date for the company's sales and revenue release, giving investors the next fixed reporting point.

First-half sales rose 5.00 percent

S&P Global Ratings said on September 14, 2026 that Sandoz reported first-half 2026 net sales of USD 5.8 billion, up 5.00 percent at constant currency from USD 5.2 billion in the first half of 2025. The biosimilar segment grew 20.00 percent at constant currency, while the core EBITDA margin increased to 20.90 percent from 20.00 percent in the first half of 2025.

The figures point to a business mix that is doing more of the work. Biosimilars supplied the sharper growth contribution, but the margin comparison also matters because it shows that the sales increase was accompanied by a 0.90 percentage point improvement in the reported core EBITDA margin.

Stock sits 4.87 percent below its high

On SIX, Sandoz's latest quoted share price was CHF 72.20 on October 13, 2026 at 1:26 p.m. CEST. The CHF 47.73 to CHF 75.90 52-week range places that price 4.87 percent below the high. Trading volume was 230,590 shares against an average volume of 1,222,885 shares.

Valuation and analyst counterpoint

Sandoz had a market capitalization of CHF 31.2 billion and a price-to-earnings ratio of 58.25 on October 13, 2026. The trailing dividend yield was 0.01 percent. Markets Insider reported on October 6, 2026 that Morgan Stanley raised its target from CHF 55.00 to CHF 60.00 and kept an Underweight rating. At CHF 72.20, the SIX price stood 20.33 percent above that target, making the valuation gap a concrete counterweight to the first-half growth profile.

Comparison with peers

Sandoz (SIX, CHF): plus 1.66 percent, price-to-earnings ratio 58.25, market capitalization CHF 31.2 billion
Teva Pharmaceutical Industries (NYSE, USD): plus 0.17 percent, price-to-earnings ratio 68.53, market capitalization USD 47.9 billion
Viatris (NASDAQ, USD): minus 0.57 percent, price-to-earnings ratio minus 48.72, market capitalization USD 20.4 billion

Price stays above EUR 77

At Lang & Schwarz, Sandoz stock was trading at EUR 77.35 on October 13, 2026 at 3:38 p.m. CEST. On SIX, the stock was up 1.66 percent on the day as of October 13, 2026. The further course of trading is shown by the continuously updated real-time quote of Sandoz stock.